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INTRODUCTION
The oncogene cyclin D1 is important in the disease pathogenesis of Mantle Cell Lymphoma (MCL). It has been shown that cyclin D1 undergoes alternative cleavage and polyadenylation (APA) in MCL through some, yet unknown mechanism. In order to elucidate this mechanism, this project is subdivided into 3 specific aims. The first aim is to identify the cis-elements governing cyclin D1 proximal poly (A) site selection in MCL. In addition I will determine the role of CFIm25 and CFIIm-Pcf11 in APA of cyclin D1 in MCL. The last aim involves the global analysis of genes in MCL cancer cells whose pPAS usage is regulated by CFIm-25 and CFIImPcf11. This first year progress report will describe the progress made so for specific subsections of all three aims. In brief, we have successfully shown that CFIm25 plays a major role in global regulation of APA in cyclin D1 and other genes. To put the progress made in light of the specific aims into perspective, the following section will provide a brief review on the background in the field.
The role of Cyclin D1 in MCL
Overexpression of the G1-S phase cell cycle regulating oncogene cyclin D1 in MCL occurs as a result of a t(11;14)(q13;q32) chromosomal translocation that places cyclin D1 under the control of B-cell IgH genes transcription enhancers [1] . This overexpression of cyclin D1 contributes to the proliferative signature, which determines the rate of tumor proliferation and patient survival [2] . In addition to the chromosomal translocation, studies have shown that MCL patients that express cyclin D1 with a longer 3'UTR survived longer (3.28 years) than patients who expressed the truncated isoform (1.38 years) [3] . The long and the short cyclin D1 transcripts have the same open reading frame and code for the exact same protein. They only differ in the length of their 3'UTRs [3, 4] . Shortening of the cyclin D1 3'UTR in some MCL patients is due to genomic deletions. In other cases, mutations occur providing a stronger proximal PAS (pPAS) that is then used instead of the more distal PAS (dPAS) [3] through APA. However there are still cases of APA in MCL, which do not involve mutations that generate a stronger pPAS and how the pPAS is selected for use in these cases is still unknown. Hence the working hypothesis is that in MCL cells, cyclin D1 pPAS selection is regulated by cis elements adjacent to it. This is investigated in Aim 1.
Alternative Cleavage and Polyadenylation (APA)
Similar to what is seen in cyclin D1, most cases of alternative cleavage and polyadenylation(APA) involve using alternative polyadenylation signals (PAS) within the same terminal exon [5] . Usage of the pPAS results in shortening of the 3'UTR may result in the elimination of destabilizing elements including miRNA binding sites and AU-rich destabilizing elements ( Figure 1 ). The resulting truncated mRNA transcripts are more stable resulting in increased translation [6] . Shortening of the 3'UTR is widespread and has been observed in rapidly proliferating cells [7] and has been implicated in tumorigenesis [6, 8] . Ongoing work in the field seeks to identify all the factors that regulate APA in cancer. We hypothesized that alterations in the levels of 3'end cleavage and polyadenylation factors determine PAS site choice. This is the goal of Aim 2.
Identification of genes in MCL that undergo APA
Since the discovery of several oncogenes that undergo APA in cancer by Mayr et al using Northern blots [6] , next generation sequencing has been extensively used to identify APA changes on a global scale. Besides cyclin D1, the genes that undergo shortening in MCL are still unknown. Preliminary studies in our lab led us to hypothesize that the there are other genes undergoing APA besides cyclin D1in MCL cancer cells. This will be the focus of Aim 3.
BODY
Both the negative and positive outcomes for this second year of research will be reported in this section. Research for the three aims were performed concurrently and the results will be presented for each specific aim and linked to the task listed in the Statement of Work (SOW). The progress for the second year is presented following work done in the first year to show the positive and negative outcomes for this time period relative to what was done in the first year.
Specific Aim 1:
Identify the cis-elements governing cyclin D1 proximal poly (A) site selection in MCL.
Aim 1 a and b. Clone cyclin D1 upstream of EGFP in pcDNA3.1 plasmid and check for expression. Perform site directed mutagenesis to eliminate any stop codons and within Cyclin D1. Although EGFP had already been cloned into pcDNA3.1, the plasmid did not have a tag for checking expression, so efforts were made to clone a fragment of the 3'UTR (~300nts) of cyclin D1 sequence downstream of the Myc-tagged GFP expressing plasmid pcDNA4 instead. The expected results were that if the cyclin D1 proximal PAS is used, there will be no expression of GFP. However if the GFP PAS is used instead, there will be GFP expression ( Figure 2 , left panel). The cherry plasmid was co-transfected with the pcDNA4 plasmid to correct for transfection efficiency. As shown (Figure 2 , right panel) Cyclin D1 was successfully cloned in frame with GFP and we can still detect GFP expression. However, this reporter system did not attenuate GFP signal as was expected, i.e. the cyclin D1 pPAS was not used. In addition, cotransfection with cherry did not result in a reproducible immunofluorescence signal suggesting that co-transfection may alter the transfection efficiency of each plasmid.
There are a number of possibilities why the cyclin D1 pPAS was not used. It is possible that the cyclin D1 3'UTR fragment used was too short and did not include all the cis elements required for proper processing. To address this, 2 longer cyclin D1 3'UTR fragments (both >500bp) were generated ( Figure 3 ) and cloned into the dual luciferase plasmid psi-check 2 (Promega). In this plasmid the cyclin D1 3'UTR plasmid fragments are cloned downstream of the human Renilla luciferase gene translational stop codon. The advantage of using this plasmid is that it also has human firefly luciferase cloned within the same reporter system allowing for intra-plasmid normalization of transfection eliminating problems observed with co-transfection of 2 different plasmids. This dual cassette reporter system is amenable to detecting effects of RNAi on cyclin D1 half-life which is one of the goals for Specific Aim 2. Since we now have the required clones, we can now proceed with site-directed mutagenesis to identify cis-elements and to mimic mutations observed in MCL. 
Aim 2a.
Optimize RNAi in Jeko-1 and RPMI 1788
In this aim the goal is to knock down CFIm25 and Pcf11 in RPMI 1788 normal B-cells and in the MCL cell line Jeko-1. MCL cells have been reported to be extremely difficult to transfect. In our lab we have developed a Lipofectamine based RNAi protocol that has worked in most of the cell lines we have tested so far, with a very high degree of knockdown achieved. Here we show that when we used two different siRNAs against CFIm25 in HeLa and A549 cells we were able to deplete CFIm25 levels ( Figure 5a ). However, we were unsuccessful in using the same technique to knockdown CFIm25 in RPMI and Jeko-1 (Figure 5b ). Efforts are ongoing and in addition to use other transfection reagents we plan to use Nucleofactor, which has been reported in the literature to work on MCL cells.
This Aim was giving the most problems. However, I have finally managed to successfully to perform RNAi in the B-cell lines by using electroporation and the Nucleofector kit from Lonza. The first objective was to see if I could knockdown cyclin D1 since it is highly expressed in the MCL cell lines. Cyclin D1 was successfully depleted in both the Jeko-1 and Granta cell lines ( Figure 6 ).
Aim 2b. Develop RNAi resistant forms of CFIm-25 and CFIIm-Pcf11
One of the goals of this project is to use RNAi resistant plasmids to perform RNAi and rescue experiments. In collaboration with Scott Collum, a graduate student in the lab, we have developed RNAi resistant CFIm25 expression plasmid in Myc-HA-tagged pcDNA3 ( Figure 7) . One of the genes that underwent 3'UTR shortening after CFIm25 depletion was glutaminase (GLS) resulting in increased protein levels ( Figure 7 ). As proof of principle, when CFIm25 siRNA was co-transfected with the CFI25m RNAi resistant plasmid, it was able to abrogate the increase in GLS protein levels ( Figure 7 ).
Aim 2e. Determine effects of RNAi/overexpression on cell cycle and cell proliferation Since cyclin D1 drives the G1-S phase of the cell cycle, one of our goals is to investigate the effect of CFIm25 siRNA on cell proliferation in MCL. Preliminary data in HeLa cells shows that depletion of CFIm25 results in increased cell proliferation ( Figure 8 ). However, the number of cells after Figure 6 . Western blot of Jeko-1 and Granta cell lysates after knockdown with either a control (Con.) or a Cyclin D1 (CCND1) specific siRNA. depletion of Pcf11 is comparable to the control. When CFIm25 was over-expressed in U251 cells, there was a decrease in cell proliferation.
Mantle cell lymphoma patients are often diagnosed in stages III and IV with both bone-marrow involvement and leukemic spread [9] . Hence in addition to changes in cell proliferation other assays have to be used to assay for increased tumorigenicity. Although I was able to knockdown CFIm25 in MCL, the electroporation technique resulted in reduced cell numbers since some of the cells did not recover from the process. Therefore I knocked down CFIm25 in the glioblastoma cell line, LN229 ( Figure 9 ) and performed both anchorage dependent and matrigel invasion assays. Depletion of CFIm25 resulted in decreased colony formation and increased cell invasion. Hence RNAi of CFIm25 in several different cell lines increases their tumorigenicity. A closer look at both the cyclin D1 and Timp2 terminal 3'UTR RNA-Seq. data ( Figure 11 ) shows that there is a decrease in read density in the 3'UTR after CFIm25 depletion similar to previous results we obtained using qRT-PCR primers that allow us to distinguish between distal and proximal PAS usage. This RNA-Seq. data is important because: First it validates our previous qRT-PCR data that CFIm25 depletion results in 3'UTR shortening of cyclin D1 due to increased pPAS usage. Second, any changes in the 3'UTR length can be detected by analysis RNA-Seq data read density.
Since analysis of the RNA-Seq data by eye is cumbersome and non-quantitative, our lab entered into a collaboration with Dr. Wei Li, a Bioinformaticist from Baylor
College of Medicine whose lab specializes in developing complex algorithms to analyze genome wide sequencing data. Dr. Wei Li and his postdoctoral fellow, Dr. Zheng Xia developed a customized algorithm that is able to detect and quantify changes in 3'UTR length between samples. The change in usage of the dPAS between samples is then quantified as the percentage dPAS usage index (∆PDUI). From this we identified 1002 transcripts that were shortened by usage of the pPAS after CFIm25 depletion, and only 5 transcripts that were lengthened ( Figure 12 ). This suggests that CFIm25 is a global repressor of pPAS usage. The algorithm also allows us to identify novel cases of APA not annotated in any database. Shown here ( Figure 13 ) are Vma21, FGF2, MSRB3 and TMEM48 which undergo APA after CFIm25 depletion. There are also some genes that are unaffected by loss of CFIm25 despite having long 3'UTRs and the two examples shown are FHL-1 and CRTC3.
Despite successfully performing RNA-Seq. on HeLa cells last year, we had to redo the RNA-Seq. analysis in duplicate to validate that the results were reproducible according to the ENCODE Consortium Standards, Guidelines and Best Practices for RNA-Seq. We decided to perform this in the HeLa cells so we could have several (n=3) biological replicates, and compare the RNA-Seq. results from one sample that was run months before. Below (Table 2 ) is a summary of the RNA-Seq. data performed in duplicate [10] . There were two control replicates (Con. R1 and Con. R2), and the duplicate CFIm25 knockout (CFIm25 KDR1 and CFIm25KD R2). Interestingly we managed to get almost double the number of reads as we obtained with our trial sample ( Table 2 vs. Table 1 ), increasing our level of confidence in the sequencing process. As a proof of principle, we analyzed the read density map of several genes from all three RNA-Seq runs side by side to test for reproducibility. Shown are the read density maps from three genes(Vma21, SMOC1 and FHL1) and they are all consistently reproducible ( Figure 14 ). Furthermore, re-analysis of the two replicates using our previously developed algorithm resulted in an increase in the number of genes from that had their 3`UTR shortened from 1,002 ( Figure 12 ) to 1,450 after CFIm25 depletion (Figure 15 ) due to the increase in the RNA reads ( Table 2) Since one of the goals of this aim was to identify the genes that are regulated by CFIm25 and Pcf11 in MCL cells I had to first determine the levels of each of these two factors in the different cell lines.
Aim 3d. Validate 3P-Seq results on a gene by gene basis using qRT-PCR and map PAS used by 3'RACE.
To validate the results from RNA-Seq. amplicons were designed ( Figure 17 ) for a few select genes to detect changes in distal pPAS usage normalized to total mRNA for each gene. When compared to the normal B-cell line RPMI1788, the levels of CFIm25 are significantly decreased in Jeko-1 and Mino and slightly decreased in Granta and SP53. There are reduced levels of Pcf11 in RPMI 1788 compared to three of the MCL cell lines Jeko, Granta and SP53. Hence, both these factors may therefore be involved in regulating APA in MCL. Quantitative RT-PCR (qRT-PCR) was used to detect APA after CFIm25 depletion using 2 different siRNAs. As shown ( Figure 18 , left panel), qRT-PCR was able to validate RNA.Seq. data of 2 genes that were unaltered by CFIm25 depletion and several genes that switched from dPAS to pPAS usage after CFIm25 knockdown. Western blot analysis was then performed to test whether this increase in pPAS usage correlates with increased protein expression. There were significant increase in protein levels for several genes which correlates with a switch to the pPAS resulting in the generation of more stable transcripts. Most notably there were increases seen in levels of glutaminase (GLS), MecP2 and cyclin D1 ( Figure 18 , right panel) which have been directly associated with increased cell proliferation characteristic of the transformed cell phenotype. This also correlates with increased cell proliferation, which was observed in Figure  8 . Most notably, we see changes in APA correlating with increased levels of oncogenic cyclin D1, a main driver of MCL pathogenesis.
KEY RESEARCH ACCOMPLISHMENTS (2013-2014)
• CFIm25 is a global regulator of APA for over 1,400 genes including cyclin D1 • The changes from dPAS to pPAS usage regulated by CFIm25 depletion corresponds with enhanced tumorigenicity as shown by increased cell proliferation, cell invasion and anchorage dependent growth • We have identified electroporation as a viable technique to use to perform RNAi in MCL • We have also validated that our RNA-Seq. analysis data is highly reproducible by redoing RNASeq. in duplicate. 
REPORTABLE OUTCOMES (

CONCLUSIONS
This second year research progress report builds upon work done in the first year. Successfully knocking down cyclin D1 in MCL by electroporation opens an avenue that will allow us to perform further RNAi experiments in these cells. Differences in levels of CFIm25 and Pcf11 between the MCL cell lines and Pcf11lends further credence to our hypothesis that these two factors may be involved in regulating APA in MCL. We will choose one cell MCL cell line and compare it to the normal B-cell line for the RNASeq. experiments planned in MCL. Furthermore, the reproducibility of the RNA-Seq. data in HeLa and increased tumorigenicity observed after CFIm25 RNAi in HeLa will act as the basis for our continued proposed MCL based research. The global shortening of messenger RNAs through alternative polyadenylation (APA) that occurs during enhanced cellular proliferation represents an important, yet poorly understood mechanism of regulated gene expression 1, 2 . The 39 untranslated region (UTR) truncation of growth-promoting mRNA transcripts that relieves intrinsic microRNA-and AU-rich-element-mediated repression has been observed to correlate with cellular transformation 3 ; however, the importance to tumorigenicity of RNA 39-end-processing factors that potentially govern APA is unknown. Here we identify CFIm25 as a broad repressor of proximal poly(A) site usage that, when depleted, increases cell proliferation. Applying a regression model on standard RNA-sequencing data for novel APA events, we identified at least 1,450 genes with shortened 39 UTRs after CFIm25 knockdown, representing 11% of significantly expressed mRNAs in human cells. Marked increases in the expression of several known oncogenes, including cyclin D1, are observed as a consequence of CFIm25 depletion. Importantly, we identified a subset of CFIm25-regulated APA genes with shortened 39 UTRs in glioblastoma tumours that have reduced CFIm25 expression. Downregulation of CFIm25 expression in glioblastoma cells enhances their tumorigenic properties and increases tumour size, whereas CFIm25 overexpression reduces these properties and inhibits tumour growth. These findings identify a pivotal role of CFIm25 in governing APA and reveal a previously unknown connection between CFIm25 and glioblastoma tumorigenicity.
Recently, it has become increasingly clear that mRNA 39-end formation is subject to dynamic regulation under diverse physiological conditions [2] [3] [4] [5] . Over 50% of human genes have multiple polyadenylation signals, thereby increasing the potential diversity in mRNA transcript length 6 . The formation of mRNA transcripts using these distinct poly(A) sites (PASs) is carried out by APA, with the most common form involving differential use of alternative PASs located within the same terminal exon (reviewed in ref. 7) . Processing at the PAS most proximal to the stop codon (pPAS) removes negative regulatory elements that reduce mRNA stability or impair translation efficiency, such as AUrich elements (AREs) 8 and microRNA (miRNA) targeting sites 9, 10 . It has been reported that both rapidly proliferating cells 1,2 and transformed cells 3, 11 preferentially express mRNAs with shortened 39 UTRs. Despite these observations, the mechanisms that control the extensive distalto-proximal PAS switch observed in proliferative and/or transformed cells, the relationship between cause and effect, and the critical target genes subject to this regulation, are not well characterized.
To measure relative changes in endogenous APA events, we devised a quantitative polymerase chain reaction after reverse transcription (qRT-PCR) assay to monitor the transcript-specific use of the distal PAS (dPAS) while normalizing for total mRNA levels for three test transcripts, cyclin D1 (CCND1), DICER1 and TIMP2, known to undergo APA 3, 12 . Using this approach, we readily detected appreciable usage of dPASs for all three genes in HeLa cells (Extended Data Fig. 1 ). This was somewhat surprising given their highly transformed state, but is consistent with previous reports that not all transformed cells tested exhibit appreciable 39 UTR shortening 1, 3 . Previous studies implicate multiple members of the cleavage and polyadenylation (CPA) machinery as potentially regulating poly(A) site selection [12] [13] [14] [15] . To test the relative contribution of these factors to the APA of the three test genes, we used systematic RNA interference (RNAi) (Fig. 1a-c) . We observed only small changes in the relative use of the dPAS after knockdown of members of the cleavage and polyadenylation specificity factor (CPSF), cleavage stimulation factor (CSTF) and cleavage factor IIm (CFIIm) complexes (Fig. 1d-f) . By contrast, we detected significant reduction in dPAS usage after knockdown of the members of the CFIm complex. These results are consistent with a recent report that CFIm68 depletion decreases 39 UTR length 14 ; however, the most notable PAS switching was found to occur after knockdown of CFIm25. We therefore focused all further analyses on CFIm25.
Traditional methods of global PAS profiling use mRNA partitioning and digestion to sequence poly(A) junctions within messages 1, 16, 17 . To identify global targets of CFIm25 with a more streamlined approach requiring less sample manipulation, we performed high-depth (.3 3 10 8 reads) RNA sequencing (RNA-seq) after knocking down CFIm25 in parallel with a control knockdown. We determined that 23% of RNA-seq reads can be uniquely mapped to 39 UTRs of expressed genes leading to approximately 200-fold sequence coverage (Extended Data Fig. 2a, b) . We first analysed the three test genes and observed markedly reduced read density within the 39 UTRs in response to CFIm25 depletion (Fig. 2a) . These results not only confirm our qRT-PCR findings that HeLa cells robustly use the dPAS for all three test genes under basal conditions but also demonstrate that considerable 39 UTR shortening induced by CFIm25 knockdown is readily visualized by analysing the read density of RNA-seq data.
On the basis of this promising observation, we applied a novel bioinformatics algorithm termed 'dynamic analysis of alternative polyadenylation from RNA-seq' (DaPars; see Methods) for the de novo identification of all instances of 39 UTR alterations between control and CFIm25 knockdown cells, regardless of a pre-annotated pPAS within each RefSeq transcript. DaPars uses a linear regression model to identify the exact location of this novel proximal 39 UTR as the optimal fitting point (Fig. 2b, red point) as well as the abundance of both novel and annotated UTRs. The degree of difference of 39 UTR usage between the samples was then quantified as a change in percentage dPAS usage index (DPDUI), which is capable of identifying lengthening (positive index) or shortening (negative index) within the 39 UTR. When applied to the 12,273 RefSeq transcripts whose average terminal exon sequence coverage is more than 30-fold, DaPars identified 1,453 transcripts possessing a significant, reproducible shift in 39 UTR usage in response to CFIm25 depletion ( Fig. 2c and Extended Data Fig. 2c, d) . Notably, among this group of transcripts, 1,450 are shifted to pPAS usage in CFIm25 knockdown cells. We found a significant enrichment of the CFIm25 UGUA binding motif and previously reported CFIm25 iCLIP sequence tags 14 within 39 UTRs that shortened after CFIm25 knockdown relative to transcripts exhibiting no length change (Extended Data Fig. 3 ). 
LETTER RESEARCH
Moreover, we determined that 70% of transcripts whose 39 UTR is shortened after CFIm25 knockdown use a pPAS within the first one-third of their 39 UTR. By contrast, only 29% of multi-PAS transcripts that did not alter 39 UTR length in response to CFIm25 have an annotated pPAS in the first third of their 39 UTR. This demonstrates that CFIm25 APA targets are enriched with pPASs positioned close to the stop codon to maximize their degree of 39 UTR shortening. Collectively, these results clearly indicate that the function of CFIm25 is to broadly repress proximal poly(A) site choice, and consequently, the shortening of 39 UTR length is considerable for the majority of CFIm25-regulated transcripts upon its depletion.
One potential consequence of 39 UTR shortening in CFIm25 knockdown is the loss of miRNA-binding sites and/or AREs, resulting in truncated mRNA transcripts that evade negative regulation. Although the correlation between transcript expression change and DPDUI was modest (Pearson correlation 5 20.25), it does reveal that transcripts with shorter 39 UTR in CFIm25 knockdown cells have overall higher expression levels (Fig. 2d) . We observed that 64% of transcripts with shortened 39 UTRs exhibited significantly increased steady-state levels, 34% were unchanged, and only 2% were significantly reduced (Extended Data Fig. 4) . We have also organized the list of CFIm25-regulated genes with respect to their DPDUI score, change in relative levels of transcript, and predicted numbers of ARE motifs and miRNA target sites lost after APA (Supplementary Table 1 ) and observed that gene expression positively correlates with the number of lost ARE motifs and miRNA target sites (Extended Data Fig. 5 ). Several examples of novel genes whose APA is regulated by CFIm25 are shown in Fig. 2e and it is important to note that not all long 39 UTRs were observed to shorten in response to CFIm25 knockdown, indicating that the CFIm complex regulates many, but not all genes capable of APA (Fig. 2f) . Collectively, these data demonstrate the power and ease of the DaPars algorithm to identify APA within standard RNAseq, and indicate that the major form of CFIm25 regulation is to repress pPAS choice at a global level.
To validate the DPDUI results, we created qRT-PCR amplicons to monitor dPAS usage of six genes whose 39 UTRs were found to be shortened after CFIm25 knockdown and two that were not altered. Using these amplicons, we analysed RNA isolated from cells effectively depleted of CFIm25 using two independent short interfering RNAs (siRNAs) (Fig. 3a, inset) , and observed high congruence between qRT-PCR results and those obtained using RNA-seq and DPDUI (Fig. 3a, graph) . To test formally for the presence of de-repressed protein expression from mRNAs with shortened 39 UTRs, we measured their levels in lysates from knockdown cells (Fig. 3b) . We observed considerable increases in protein levels of CFIm25 target genes, including several that have a well-documented role in tumour growth, such as cyclin D1, glutaminase and methyl-CpG-binding protein 2 (MECP2) [18] [19] [20] [21] [22] . It is worth noting that the 39 UTR of each of these genes has been shown to be subject to miRNA-mediated inhibition [23] [24] [25] . Consistent with this observation, we also noted enhanced cellular proliferation in response to knockdown of CFIm25 relative to control knockdown in HeLa cells (Fig. 3c) . Finally, to determine whether the 39 UTR is sufficient to elicit translational derepression of a heterologous protein in response to CFIm25 knockdown, we used reporters with the SMOC1 39 UTR cloned downstream of luciferase or the GAPDH 39 UTR, which was not found to alter its poly(A) site usage. We observed that only the luciferase activity specifically resulting from the luciferase-SMOC1 reporter was increased in response to knockdown of CFIm25 (Fig. 3d) , supporting the idea that the increased expression of endogenous SMOC1 protein when CFIm25 is depleted is mediated through its 39 UTR.
The collective observations that CFIm25 depletion leads to broad 39 UTR shortening, enhanced expression of growth promoting genes and increased cell proliferation support the hypothesis that CFIm25 is a novel anti-proliferative gene whose levels may be reduced in human cancers. We focused our analysis on glioblastoma, as recent reports indicate that brain tissue possesses the longest 39 UTRs 26, 27 . We reasoned that tumours derived from these cells might be more sensitive to changes in CFIm25 levels than other cancers. To test this prediction, we downloaded archived patient RNA-seq data from The Cancer Genome Atlas (TCGA), stratified it according to CFIm25 expression, and analysed it using DaPars. Indeed, following the same cut-offs in our HeLa RNA-seq 39 UTR analysis, we identified 60 genes with altered 39 UTRs, with 59 of those experiencing shortening in glioblastoma expressing lower levels of CFIm25 (Fig. 4a and Supplementary Table 2 ). Among those genes, a significant number of events (24 genes; P 5 2.2 3 10 212 by hypergeometric testing) were also shortened in CFIm25 knockdown HeLa cells and this percentage of overlap increased markedly to 86% as the DPDUI cut-off increased from 0.2 to 0.4 (Extended Data Fig. 6 ). Two representative examples of genes, FOS-related antigen 2 (FRA2; also known as FOSL2) and MECP2, with shortened 39 UTRs in low CFIm25-expressing glioblastoma tumours is shown in Fig. 4b , demonstrating a compelling similarity between the patient samples and HeLa cells before and after CFIm25 knockdown. Overexpression of either of these genes has been shown to enhance cell proliferation 18, 28 . To test formally whether altering CFIm25 expression can modulate glioblastoma tumorigenic properties, we screened a panel of glioblastoma cell lines and observed that U251 cells naturally express lower levels of CFIm25 compared with LN229 cells (Fig. 4c) . To raise CFIm25 levels in U251 cells, we created cell lines stably expressing either Myc-tagged CFIm25 or green fluorescent protein (GFP) as a control. In parallel, we used RNAi to reduce CFIm25 levels in LN229 cells (Fig. 4c) . We observed a significant reduction in anchorage-dependent growth and cellular invasion in U251 cells overexpressing CFIm25 compared with the GFP control, whereas reducing CFIm25 in LN229 cells caused an increase in both of these properties (Extended Data Fig. 7 ). To determine if the altered in vitro properties of glioblastoma cells affected tumour growth kinetics in vivo, we used a subcutaneous xenograft model. Increased expression of CFIm25 in U251 cells resulted in a marked reduction in tumour growth and decreased tumour cell proliferation (Fig. 4d and Extended Data Fig. 8 ). By contrast, depletion of CFIm25 in LN229 cells caused a profound increase in tumour size (Fig. 4e and Extended Data Fig. 9 ). Collectively, these results uncover a tumour suppressive property of CFIm25 in glioblastoma that is probably mediated through its broad repression of APA-dependent mRNA 39 UTR shortening.
We identified CFIm25 among 15 cleavage and polyadenylation factors as a key factor that broadly regulates APA. Importantly, the data presented here also extend our understanding of APA in regulated gene expression through the demonstration that extensive shortening of 39 UTRs causally leads to enhanced cellular proliferation and tumorigenicity, probably through the upregulation of growth promoting factors, such as cyclin D1. These results indicate the importance of 39 UTR usage in cell growth control and underscore the need for further research into the mechanism and regulation of APA and its potential links to other human diseases.
METHODS SUMMARY
Human cell lines used were cultured using standard techniques. RNAi and western blot experiments were conducted as described previously 29 . For luciferase experiments, one day after the second siRNA hit, cells were transfected with 39 UTR Renilla luciferase plasmids and activity was assayed after 24 h. Total RNA for pRT-PCR was reverse transcribed using MMLV-RT (Invitrogen). qRT-PCR reactions were performed using SYBRGREEN (Fermentas). Duplicate control and CFIm25 knockdown samples were sequenced by HiSeq 2000. RNA-seq reads were aligned (hg19) using TopHat 2.0.10 30 . All the TCGA glioblastoma RNA-seq BAM files were downloaded from the UCSC Cancer Genomics Hub (https://cghub.ucsc.edu/). DaPars was used to identify differential 39 UTR usage from RNA-seq (Z.X. et al., unpublished observations; https://code.google.com/p/dapars). For tumour xenografts, U251 cells were stably transfected with GFP or CFIm25 plasmids. LN229 cells were transfected with lentivirus expressing CFIm25 shRNA. After subcutaneous injection of cell lines into nude mice, glioblastoma tumour size was monitored and tumours were removed and histologically analysed.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. . A statistical summary of read alignments and average gene expressions can be found in Extended Data Fig. 2 . More than 12,000 (,50%) human RefSeq genes can be detected through RNA-seq with expression levels more than 1 fragments per kilobase of transcript sequence per million mapped paired-end reads (FPKM) 32 . More importantly, the average of 23% of RNA-seq reads can be uniquely mapped to 39 UTRs of expressed genes that renders around 2003 coverage on UTRs. All the TCGA glioblastoma RNA-seq BAM files were downloaded from the UCSC Cancer Genomics Hub (CGHub; https://cghub.ucsc.edu/). Analysis of APA from RNA-seq. We used a novel bioinformatics algorithm DaPars (Z.X. et al., unpublished observations; https://code.google.com/p/dapars) for the de novo identification of APA from RNA-seq. The observed sequence coverage was represented as a linear combination of novel and annotated 39 UTRs. For each RefSeq transcript with annotated PAS, we used a regression model to infer the end point of alternative novel PAS within this 39 UTR at single nucleotide resolution, by minimizing the deviation between the observed read coverage and the expected read coverage based on a two-PAS model, in both control and CFIm25 knockdown samples simultaneously.
To quantify the relative PAS usage, we defined the percentage of dPAS usage for each sample as PDUI index. The greater the PDUI is, the more the dPAS of a transcript is used and vice versa. DPDUI. We used the following three criteria to detect the most significant shifted 39 UTR events: First, given the expression levels of short and long 39 UTRs in two samples in each condition, we compute the significance of the difference of mean PDUIs using Fisher's exact test, which is further adjusted by Benjamini-Hochberg (BH) procedure to control the FDR at a level of 5%. Second, the absolute difference of mean PDUIs must be no less than 0.2. Third, the absolute log 2 ratio (fold change) of mean PDUIs must be no less than 1. To avoid false positive estimation on low coverage transcripts, we required that there be more than 30-fold coverage on the 39 UTR region of both samples. For genes with multiple annotated PASs, we only kept the one with the greatest absolute DPDUI value. Last, we identified 1,453 transcripts possessing a significant shift in 39 UTR usage in response to CFIm25 knockdown, the vast majority of which have shortened 39 UTRs in CFIm25 knockdown. Bioinformatic analyses of 39 UTR shortening. As miRNA binding sites and other regulatory sequences such as AREs reside in 39 UTRs 33, 34 , APA has an important role in mRNA stability, translation and translocation. Indeed, it has been reported that shorter 39 UTRs produce higher levels of protein 3 . To elucidate the consequences of 39 UTR shortening, we provided the numbers of lost ARE motifs and miRNA binding sites due to the 39 UTR shortening for the transcripts shifting to proximal 39 UTR usage in CFIm25 knockdown cells (Supplementary Table 1 ). The ARE is one of the most prominent cis-acting regulatory elements found in 39 UTRs to target mRNAs for rapid degradation 35 . The eight different consensus ARE motifs, including the plain AUUUA pentamer, were retrieved from the ARE site database 35 . miRNA-mRNA binding information was based on miRNA target prediction database TargetScanHuman version 6.2 [36] [37] [38] . To limit the miRNA to high-confidence sites, we required the probability of the preferentially conserved targeting (PCT) score to be more than 0 for all highly conserved miRNA families 38 . Differentially expressed gene expression analysis. With two replicates in each group, we used edgeR 39 to call differentially expressed genes with FDR , 0.05. To better quantify gene expression with shorter 39 UTRs, we counted reads based on the coding regions of each transcript. Cell culture and cell counts. All the cell lines used (HeLa, U251 and LN229) were cultured in DMEM supplemented with 10% FBS (11% penicillin and streptomycin) in a 5% CO 2 incubator at 37 uC. Cell counts were done using a standard hemacytometer. siRNA and western blot assays. Both siRNA transfection and western blot analysis were performed as previously described 29 
